Abstracts tagged "IL-6"

Abstract Number: 436 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Study Of a Sequential Therapy Of Tocilizumab and, If Initially Inadequately Responded To Tocilizumab, Followed By Rituximab In Patients With Rheumatoid Arthritis and Inadequate Response To Traditional Disease Modifying Anti-Rheumatic Drugs (MIRAI)-Interim Analysis 2
Thomas Doerner¹, Hans Peter Tony², Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kaestner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, S. Wagner⁸, Marvin A. Peters⁹ and Christof Iking-Konert¹⁰, ¹Dept Int Med (Charite), Humdoldt Univ, Berlin, Germany, ²Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ³Division of Rheumatology, University of Munich, Munich, Germany, ⁴Ambulant Centres for Rheumatology, Rheumatologist, Ludwigsfelde, Germany, ⁵Outpatient Department of Rheumatology, Ambulantes Rheumazentrum Erfurt, Germany,, Erfurt, Germany, ⁶Centre for Inflammatory Joint Diseases, Munich, Germany, ⁷Rheumapraxis, Aachen, Germany, ⁸Internistische Schwerpunktpraxis für Rheumatologie, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰Department of Rheumatology, University Hospital Hamburg Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluates a sequential exposure to two defined biologics under rigorous study conditions within a homogeneous population of patients (pts) who inadequately…
Abstract Number: 1855 • 2013 ACR/ARHP Annual Meeting
IL-6 Promotes Systemic Bone Loss Via Upregulation Of S1PR2 In Osteoclast Precursors In a Mouse Collagen-Induced Arthritis Model
Keisuke Tanaka, Misato Hashizume, Hiroto Yoshida, Miho Suzuki and Yoshihiro Matsumoto, Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Systemic bone loss is a hallmark of rheumatoid arthritis (RA). Inflammatory cytokines such as interleukin-6 (IL-6) promote bone resorption by osteoclasts. Recent studies have…
Abstract Number: 1866 • 2013 ACR/ARHP Annual Meeting
Primary Human Cell BioMAP^® Profiling Of Methotrexate, Tocilizumab, Adalimumab, and Tofacitinib Reveals Different Mechanisms Of Action With Distinct Phenotypic Signatures
Seng-Lai Tan¹, Alison O'Mahony², Ellen L. Berg², Kandeepan Ganeshalingam³ and Ernest H. Choy⁴, ¹Inflammation, Hoffmann-La Roche, Nutley, NJ, ²BioSeek, South San Francisco, CA, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Proinflammatory cytokines cause joint inflammation and destruction in patients with rheumatoid arthritis, as exemplified by the therapeutic success of inhibiting tumor necrosis factor alpha…
Abstract Number: 1833 • 2013 ACR/ARHP Annual Meeting
Combination Of TNF and IL-6 Induces Osteoclast-Like Cells With Bone-Resorption Activity Both In Vitro and In Vivo
Kazuhiro Yokota, Kojiro Sato and Toshihide Mimura, Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Although TNF inhibitors suppress bone destruction in patients with rheumatoid arthritis (RA), TNFα stimulation alone does not directly induce osteoclasts, bone-resorbing cells. With the…
Abstract Number: 1823 • 2013 ACR/ARHP Annual Meeting
IL-6 Suppresses Osteoblast Differentiation Through The SHP2/MEK2 and SHP2/Akt2 Pathways In Vitro
Shoichi Kaneshiro¹, Kosuke Ebina¹, Kenrin Shi¹, Chikahisa Higuchi², Hideki Yoshikawa¹, Jun Hashimoto³ and Makoto Hirao⁴, ¹Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ²Osaka University Graduate School of Medicine, Suita, Japan, ³Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁴Orthopaedic Surgery, Osaka Minami Medical Center, Osaka, Japan
Background/Purpose: Interleukin-6 (IL-6), a potent inflammatory cytokine, plays a key role in the pathogenesis of rheumatoid arthritis (RA), including osteoporosis not only in inflamed joints…
Abstract Number: 1601 • 2013 ACR/ARHP Annual Meeting
The Presence Of IgG-Immune Complexes In The Cerebrospinal Fluids Is Associated With Central Neurocychiatric Manifestatin But Not With Intrathecal Production Of Proimmflammatory Cytokines/Chemokines Such as Interferon-α In Systemic Lupus Erythematosus
Taku Yoshio¹, Hiroshi Okamoto², Kazuhiro Kurasawa³, Yoshiaki Dei⁴, Shunsei Hirohata⁵ and Seiji Minota⁶, ¹Division of Rheumatology and Clinical Immunology, Jichi Medical University, School of Medicine, Shimotsuke-shi, Tochigi-ken, Japan, ²Minami-Otsuka Institute of Thechnology, Minami-Otsuka Clinic, Tokyo, Japan, ³Clinical Immunology, Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi-ken, Japan, ⁴Saiseikai Utsunomiya Hospital, Utsunomiya-shi, Tochigi-ken, Japan, ⁵Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ⁶Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke,Tochigi, Japan
Background/Purpose: IgG-Immune complexes (IC) formed by CSF autoantibodies in patients with neuropsychiatric syndromes of systemic lupus erythematosus (NPSLE) has reported to stimulate the production of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].